title: [Use of dexmedetomidine hydrochloride as a sedative during local therapy for hepatocellular carcinoma].
abstract: Sedation using dexmedetomidine hydrochloride (DEX) was administered to patients with hepatocellular carcinoma (HCC) prior to local therapy. Case 1 was a 58-year-old man undergoing radiofrequency ablation in combination with transcatheter arterial chemoembolization for HCC in S3. In accordance with the package insert, the initial loading dose was set at 6 μg/kg/hour. Although a favorable sedative effect was achieved, his blood pressure and pulse rate decreased. Case 2 was a 79-year-old woman undergoing percutaneous ethanol injection therapy for HCC in S6. Half the initial loading dose indicated in the package insert (3 μg/kg/hour) was administered, but the sedative effect was appreciable. No marked blood pressure or pulse rate decreases were observed. We believe that the use of DEX as a sedative agent in local therapy for HCC can be expected to increase. However, the optimal dose setting for DEX requires further examination.
authors.affiliation: Department of Internal Medicine, Niigata Prefectural Shibata Hospital.
authors.forename: Shunsuke
authors.initials: S
authors.lastname: Tsubata
authors.forename: Yukio
authors.initials: Y
authors.lastname: Aruga
authors.forename: Masaaki
authors.initials: M
authors.lastname: Hirano
authors.forename: Akira
authors.initials: A
authors.lastname: Sakamaki
authors.forename: Masashi
authors.initials: M
authors.lastname: Yamakawa
mesh_terms: D000368:Aged; D006528:Carcinoma, Hepatocellular / Q000628:therapy*; D017115:Catheter Ablation; D003131:Combined Modality Therapy; D020927:Dexmedetomidine / Q000627:therapeutic use*; D004621:Embolization, Therapeutic; D005260:Female; D006801:Humans; D006993:Hypnotics and Sedatives / Q000627:therapeutic use*; D008113:Liver Neoplasms / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged
chemical_list: D006993:Hypnotics and Sedatives; D020927:Dexmedetomidine